辉瑞已经在朝那方面努力了。
在辉瑞工作是最有收获的选择之一。
A career with Pfizer is one of the most rewarding choices you can make.
一度曾是制药业领军企业的辉瑞如今麻烦重重。
Because Pfizer, once the leading light of the drugs industry, is in serious trouble.
辉瑞公司支付这项新的检验。
辉瑞试图避免财务灾难而尽的最大努力也随之同逝。
With it went Pfizer's single best shot at avoiding a financial disaster.
然而，辉瑞制药也名列众多宣布大量裁员的公司之中。
Pfizer was, however, among a number of companies that announced huge job cuts.
辉瑞对舒尼替尼的乳腺癌研究已进入后期。
Pfizer is in the final stage of study generally required for u.
辉瑞说，“我们相信这个案例没有价值。”
抗癌药物曾一度不被诸如辉瑞制药等的大型制药公司看好。
Cancer was once unattractive for big pharmaceutical companies like Pfizer.
也是在昨天，辉瑞公司宣布放弃其正在实验中的抗肥胖药物。
Also yesterday, Pfizer said it was giving up on an experimental anti-obesity drug.
不过该消息人士还表示，辉瑞和艾尔建一直都有一套退出策略。
Pfizer and Allergan have always had an exit strategy in place, the source said.
不过该消息人士还表示，辉瑞和艾尔建一直都有一套退出策略。
Pfizer and Allergan have always had an exit strategy in place, the source said.
应用推荐